Not all partial tears heal conservatively, and some will progress to full tears requiring surgical intervention
This may indicate that the visual improvement from hair count alone (without thickness changes) fell short of patient expectations
Poster Session II - ACUTE ISCHEMIC STROKE MANAGEMENT 01.00 - ACUTE ISCHEMIC STROKE MANAGEMENT - 01.04 - THROMBOLYSIS P627 - ESOC25-1710 COST-EFFECTIVENESS OF THROMBECTOMY WITH OR WITHOUT ALTEPLASE FOR LARGE VESSEL OCCLUSION STROKE ACROSS 16 COUNTRIES: A META-ANALYSIS CONSIDERING TIME-TO-TREATMENT Chi Nguyen 1,2 , Fabiano Cavalcante 3 , Kilian Treurniet 3,4 , Manon Kappelhof 4 , Wenjie Zi 5 , Pengfei Yang 6,7 , Kentaro Suzuki 8 , Urs Fischer, Conor Houlihan 9 , Peter Mitchell 9 , Bernard Yan 9 , Erik Buskens 1,2 , Maarten Uyttenboogaart 1 , Charles Majoie 4 , Maarten Lahr 1,10 1 University Medical Center Groningen, Groningen, Netherlands, 2 Faculty of Economics and Business, University of Groningen, Groningen, Netherlands, 3 Haaglanden Medical Center, Hague, Netherlands, 4 Amsterdam University Medical Center, location University of Amsterdam, Amsterdam, Netherlands, 5 Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, China, 6 Changhai Hospital, Naval Medical University, Changhai, China, 7 Oriental Pan-Vascular Devices Innovations College, University of Shanghai for Science and Technology, Shanghai, China, 8 Nippon Medical School, Tokyo, Japan, 9 The Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia, 10 Aletta Jacobs School of Public Health, University of Groningen, Groningen, Netherlands Background and Aims: In stroke patients presenting to thrombectomy-capable stroke centers, the benefit of combining intravenous thrombolysis (IVT) with alteplase and thrombectomy is time-dependent
No reason to expect significant rebound or withdrawal
No Published Human Trials: There are no robust, large-scale human clinical trials showing BPC 157 can safely induce or maintain clinical remission in IBD
By targeting melatonin synthesis and circadian gene expression, Epitalon could act as a molecular metronome, realigning internal timekeeping mechanisms that tend to falter with age
